Karen M. Meagher, Ph.D.

Closed for Enrollment

• Pandemic Response Optimizing Technology and Ethics for Coronavirus Teams Implementing Novel Genetics (PROTECTING) (PROTECTING) Rochester, Minn.

  The purpose of this study is to explore lay understandings toward participating in and perceptions of consent to biospecimen research and valuation of genetics in SARS-COV-2 infection, testing, immunity, and vaccine development, to explore professional attitudes toward and perception of barriers and facilitators for implementating genetic technology to facilitate understanding of SARS-COV-2 infection and immunity, improvement and scale-up of testing, and vaccine development, and to identify ethical, social, and inter-professional aspects of microbial genetic technology implementation in population health surveillance, clinical test development, and vaccine research.We hypothesize that engagement with individuals whom directly experience and/or are impacted by the increasing use of SARS-Cov-2 genetic technology, including COVID-19 Pandemic Response Biobank contributors and interdisciplinary expert teams will help identify ethical and social issues in adopting and implementing emerging technology.

   

• PaSAGE: Patient Centered Approaches to Gene Editing Research (Deliberations) (PaSAGE) Rochester, Minn., Jacksonville, Fla.

  The purpose of this study is to elicit lay, lived experience, and experts’ ethical concerns, clinical aspirations and governance needs regarding prenatal gene editing technologies. 

• PaSAGE: Patient Centered Approaches to Gene Editing Research (Key Informants) (PASAGE) Jacksonville, Fla., Rochester, Minn.

  The purpose of this study is to elicit clinicians’ and scientists’ views, ethical concerns, clinical aspirations and governance needs regarding prenatal gene editing technologies. 

• Stewardship, Technology, and Ethics Within Antimicrobial Resistance Diagnostics and Surveillance Pilot Study (STEWARDS) Rochester, Minn.

  The  purpose of this study is to explore ethical, legal, and social implications (ELSI) of stakeholder attitudes toward new genomic technologies, including the contribution of these new advances to AM stewardship, to understand how stakeholder views and expectations of ethical issues and microbial technologies are shaped by a sense of professionalism and moral responsibility for clinical roles, population health outcomes, and health system policies, and to identify barriers and facilitators as microbial technologies are integrated into treatment decisions that also serve AM stewardship goals.